Champalimaud Foundation

Champalimaud Foundation
D. Anna de Sommer Champalimaud and Dr. Carlos Montez Champalimaud Foundation
Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud

Abbreviation	Fundação Champalimaud
Named after	Anna de Sommer Champalimaud and Carlos Montez Champalimaud
Formation	June 2005
Founder	António Champalimaud
Founded at	Lisbon
Type	Non-governmental organization
VAT ID no.	PT507131827
Registration no.	507131827
Legal status	Foundation
Purpose	Scientific research in the field of medicine
Headquarters	Centro de Investigação da Fundação Champalimaud, Avenida Brasília, 1400-038 Lisbon
Services	Radiology, Nuclear Medicine, Pathology, Radiation Oncology, Chemotherapy, and Psycho-oncology
Fields	Medicine
Official language	Portuguese and English
President	Leonor Beleza
Vice-President	João Silveira Botelho
Director	António Horta Osório
Key people	António Champalimaud and Leonor Beleza
Revenue (2018)	€ 70,234,226
Expenses (2018)	€ 79,504,954
Endowment	€ 500,000,000
Staff (2018)	550
Website	www.fchampalimaud.org

The Champalimaud Foundation (Portuguese: Fundação Champalimaud) is a private biomedical research foundation. It was created according to the will of the late entrepreneur António de Sommer Champalimaud, in 2004. The complete name of the foundation honors the mother and father of the founder and is Fundação Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud. It is located in Lisbon, Portugal.^[1]

YouTube Encyclopedic

1/3
Views:
661
1 053
28 777

Transcription

Overview

The mission of the Foundation is "to develop programmes of advanced biomedical research and provide clinical care of excellence, with a focus on translating pioneering scientific discoveries into solutions which can improve the quality of life of individuals around the world."

The foundation undertakes research in the fields of neuroscience and oncology at the modernistic Champalimaud Centre for the Unknown in Lisbon, opened in 2011. Research into visual impairment is undertaken via an outreach program.

The Champalimaud Clinical Center (CCC) is a modern scientific, medical and technological institution providing specialized clinical treatment for oncology. The Center develops advanced programs for research of diseases. The CCC tries to customize the therapies in order to achieve more effectiveness in controlling and treating the diseases.^[2] It was designed by Indian architect Charles Correa.

Management

The management of the Foundation consists of Board of Directors, General Council, Scientific Committee, Ethics Committee and Vision Award Jury. The acting President is Leonor Beleza appointed by António Champalimaud in his will.^[3]

António Champalimaud Vision Award

The award was established in 2007 to recognise contributions to research into vision. In even numbered years it is awarded for contributions to overall vision research and in odd numbered years for contributions to the alleviation of visual problems, primarily in developing countries.^[4]

Recipients

Source: Champalimaud Foundation

2023: St John of Jerusalem Eye Hospital Group
2022: Gerrit Melles and Claes Dohlman, for opening new paths to treat those affected by corneal disease
2019: Instituto da Visão – IPEPO, the Altino Ventura Foundation and the UNICAMP Ophthalmology Service, longstanding organisations that have worked to prevent blindness and visual impairment by providing eye services to underserved populations in Brazil
2018: Jean Bennett, Albert Maguire, Robin Ali, James Bainbridge, Samuel Jacobson, William W. Hauswirth and Michael Redmond, for the first successful gene therapy to cure an inherited human disease
2017: Sightsavers and CBM (Christian Blind Mission), organisations with long and distinguished histories of supporting blindness prevention, alleviation and rehabilitation programmes in developing countries
2016: Christine Holt, Carol Mason, John Flanagan and Carla Shatz, for ground-breaking work that has illuminated our understanding of the way in which our eyes send signals to the appropriate areas of the brain
2015: Kilimanjaro Centre for Community Ophthalmology (KCCO), Seva Foundation and Seva Canada
2014: Napoleone Ferrara, Joan W. Miller, Evangelos S. Gragoudas, Patricia D'Amore, Anthony P. Adamis, George L. King and Lloyd Paul Aiello, for the development of anti-angiogenic therapy for retinal disease
2013: Nepal Netra Jyoty Sangh, Eastern Regional Eye Care Programme, Lumbini Eye Institute and Tilganga Institute of Ophthalmology
2012: David Williams, for the application of adaptive optics (AO) to the eye; and James Fujimoto, David Huang, Carmen A. Puliafito, Joel S. Schuman & Eric Swanson, for the development of optical coherence tomography (OCT)
2011: African Programme for Onchocerciasis Control
2010: J. Anthony Movshon and William Newsome
2009: Helen Keller International
2008: Jeremy Nathans and King-Wai Yau
2007: Aravind Eye Care System